Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron vs Tolterodine vs Combination in Women with OAB
NCT05946902Phase 4Unknown
- Sponsor
- Far Eastern Memorial Hospital
- Start
- Sep 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of mirabegron and tolterodine in overactive bladder syndrome (OAB) (3 arms), sponsored by Far Eastern Memorial Hospital. Primary endpoint: Improvement of overactive bladder symptoms at 12 weeks. Status: unknown.
02
Drugs
mirabegrontolterodine
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT05946902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05946902.